Decoy Therapeutics Inc.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
DCOY$1.10-2.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Year Ended December 31, 2025 | Year Ended December 31, 2024 | |
|---|---|---|
| Operating expenses: | ||
| Acquired in-process research and development | 8,517,966 | — |
| Research and development | 368,170 | 770,027 |
| General and administrative | 3,727,816 | 4,964,289 |
| Total operating expenses | 12,613,952 | 5,734,316 |
| Loss from operations | (12,613,952) | (5,734,316) |
| Interest income and other, net | 95,472 | 158,539 |
| Net loss | $(12,518,480) | $(5,575,777) |
| Loss attributable to common stockholders | $(12,518,480) | $(5,575,777) |
| Net loss per share attributable to common stockholders — basic and diluted | $(129.10) | $(69.54) |
| Total net loss per share | $(129.10) | $(69.54) |
| Weighted-average number of common shares used in net loss per share attributable to common stockholders — basic and diluted | 96,967 | 80,184 |
Historical common stock and additional paid-in capital amounts have been recast to reflect the 1-for-8, 1-for-15 and 1-for-12 reverse stock splits effected on June 14, 2024, August 15, 2025 and March 6, 2026, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.